|
ANTIGENICS INC, (AGEN) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Antigenics, Inc., a biotechnology company, engages in the research and development of technology and products to treat cancers, infectious diseases, and autoimmune disorders. The companys principal product candidate, Oncophage, a personalized cancer vaccine, is in phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma, as well as in phase I/II trial for lung cancer. Its product portfolio also includes AG-858, a personalized cancer vaccine in a phase II clinical trial for the treatment of chronic myelogenous leukemia; AG-702/AG-707, a therapeutic vaccine program in phase I clinical development for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for colorectal cancer and other solid tumors. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York City.
|
ANTIGENICS INC Related |
|
Antigenics Focusing on low toxicity treatments for a range of cancers, infections, and autoimmune and degenerative diseases.
|
|
Careers at Antigenics Career opportunities at Antigenics ... Antigenics' goal is to develop innovative ... Copyright © 2008 Antigenics Inc. All rights reserved. Privacy Policy ...
|
|
AGEN: Profile for Antigenics Inc. - Yahoo! Finance See the company profile for Antigenics Inc. (AGEN) including business summary, industry/sector information, number of employees, business summary, corporate ...
|
|
